KR920700643A - 면역억제제 및 그 제조방법 - Google Patents
면역억제제 및 그 제조방법Info
- Publication number
- KR920700643A KR920700643A KR1019910700795A KR910700795A KR920700643A KR 920700643 A KR920700643 A KR 920700643A KR 1019910700795 A KR1019910700795 A KR 1019910700795A KR 910700795 A KR910700795 A KR 910700795A KR 920700643 A KR920700643 A KR 920700643A
- Authority
- KR
- South Korea
- Prior art keywords
- carbon atoms
- alkyl
- hydrogen
- carbons
- represented
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
- C07D491/18—Bridged systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/485—Morphinan derivatives, e.g. morphine, codeine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D489/00—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula:
- C07D489/09—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula: containing 4aH-8, 9 c-Iminoethano- phenanthro [4, 5-b, c, d] furan ring systems condensed with carbocyclic rings or ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
- C07D491/20—Spiro-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Emergency Medicine (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Pain & Pain Management (AREA)
- Transplantation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Light Receiving Elements (AREA)
- Amplifiers (AREA)
Abstract
내용 없음
Description
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음
제1도는 본 발명의 면역억제제인 나룩시인도올(NLL)의 농도변화에 의한 길항작용을 표시하는도 제2도는 나르톨인도올(NTI)의 농도변화에 의한 길항작용을 표시하는 도이다.
Claims (8)
- δ-오피오이드 안타고니스트 또는 그 약리학적으로 허용되는 염을 유효성분으로 하는 것을 특징으로 하는 면역억제제.
- 제1항에 있어서, 전기한 S-오피오이드 안타고니스트는 일반식[Ⅰ][식중, R1은 탄소수 1내지 5의 알킬, 탄소수 3내지 6의 시클로알킬알킬, 탄소수 5내지 7의 시클로 알케닐알킬, 아릴, 아랄킬, 탄소수 4내지 5의 트랜스알케닐, 알릴 또는 푸란-2-일알킬을 표현하고, R2는 수소, 히드록시 또는 탄소수 1내지 5의 알카노일옥시를 표현하며, R3는 수소, 탄소수 1내지 5의 알킬 또는 탄소수 1내지 5의 알카노일을 표현하고, M은 질소 또는 메탄올 표현하며, R4와 R5는 별개로 수소, 불소, 염소, 취소, 아미노, 니트로, 탄소수 1내지 5의 알킬, 탄소수 1내지 5의 알콕시 또는 R4, R5을 결합하여 벤조를 표현한다]으로 표시되는 것을 특징으로 하는 면역억제제.
- 제1항에 있어서, 전기한 δ-오피오이드 안타로니스트는 일반식[2]
- 제2항에 있어서, 일반식[1]에 있어서, R1은 탄소수 1내지 5의 알킬, 탄소수 3내지 6의 시클로알킬알킬, 탄소수 5내지 7의 시클로알케닐, 알킬, 탄소수 7내지 10의 아랄킬, 탄소수 4내지 5의 트랜스알케닐, 알릴 또는 푸란-2-이소알킬이고, R2는 수소 또는 히드록시이며, R3은 수소이고, R4는 수소, 불소, 메틸, 메톡시 또는 니트로이며, R5는 수소, X는 산소 또는 NR6(여기서, R6은 수소 또는 탄소수 1내지 5의 알킬)인 것을 특징으로 하는 면역 어제제.
- 제4항에 있어서, 전기한 일반식[Ⅰ]로 표시되는 S-오피오이드 안타고니스트는 하기식[3]으로 표현되는 것을 특징으로 하는 면역억제제.[식중, R1은 탄소수 1내지 5의 알킬, 탄소수 3내지 6의 시클로알킬알킬, 탄소수 5내지 7의 시클로알케닐알킬, 아릴, 아랄킬, 탄소수 4내지 5의 트랜스알케닐, 알릴 또는 푸란-2-일알킬을 표현하고, R는 수소,히드록시 또는 탄소수 1내지 5의 알카노일옥시를 표현하며, R는 수소, 탄소수 1내지 5의 아킬 또는 탄소수 1내지 5의 알카노일을 표현하며, X는, 산소, 유황 또는 Y가 결합한 질소를 표현하고, Y는 수소 또는 탄소수 1내지 5의 알킬기를 표현하며, R와 R은 별개로 수소, 불소, 염소, 취소, 아미노, 니트로,탄소수 1내지5의 알킬, 탄소수 1내지 5의 알콕시 또는 R, R을 결합하여 벤조를 표현한다]으로 표시하는 것을 특징으로 하는 면역억제제.
- 제4항에 있어서, 전기한 일반식[1]으로 표현되는 δ-오피오이드 안타로니스트는 하기식[4]으로 표현되는 것을 특징으로 하는 면역억제제.
- 제4항에 있어서, 전기한 일반식[1]으로 표현되는 δ-오피오이드 안타로니스트는 하기식[5]으로 표현되는 것을 특징으로하는 면역억제제.
- 나르트렉숀 또는 그 염과 페닐히드라린 유도체를 용매 속 메탄술폰산 존재하에 반응시키는 것을 특징으로 하는 하기식[6].[식중, R은 수소, 염소, 취소, 불소, 메틸, 메톡시 또는 니트로를 표현한다]으로 표시되는 나트롤인도을 유도체의 제조방법.※ 참고사항 : 최초출원 내용에 의하여 공개되는 것임.
Applications Claiming Priority (10)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP30849189 | 1989-11-28 | ||
JP1-308491 | 1989-11-28 | ||
JP???1-?308491? | 1989-11-28 | ||
JP???1-?322160? | 1989-12-11 | ||
JP32216089 | 1989-12-11 | ||
JP1-322160 | 1989-12-11 | ||
JP1-326941 | 1989-12-15 | ||
JP???1-?326941? | 1989-12-15 | ||
JP32694189 | 1989-12-15 | ||
PCT/JP1990/001541 WO1991007966A1 (fr) | 1989-11-28 | 1990-11-28 | Immunosuppresseur et procede de preparation d'un tel medicament |
Publications (2)
Publication Number | Publication Date |
---|---|
KR920700643A true KR920700643A (ko) | 1992-08-10 |
KR940008032B1 KR940008032B1 (ko) | 1994-09-01 |
Family
ID=27338974
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1019910700795A KR940008032B1 (ko) | 1989-11-28 | 1990-11-28 | 면역억제제 및 그 제조방법 |
Country Status (14)
Country | Link |
---|---|
US (1) | US5332818A (ko) |
EP (1) | EP0456833B1 (ko) |
JP (1) | JP2906654B2 (ko) |
KR (1) | KR940008032B1 (ko) |
AT (1) | ATE119039T1 (ko) |
AU (1) | AU639053B2 (ko) |
CA (1) | CA2045481C (ko) |
DE (1) | DE69017434T2 (ko) |
DK (1) | DK0456833T3 (ko) |
ES (1) | ES2069100T3 (ko) |
FI (1) | FI913583A0 (ko) |
GR (1) | GR3015266T3 (ko) |
NO (1) | NO912940L (ko) |
WO (1) | WO1991007966A1 (ko) |
Families Citing this family (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5852030A (en) * | 1992-09-29 | 1998-12-22 | Toray Industries, Inc. | Indole derivatives, process for producing the same and medicinal uses of the same |
WO1994007896A1 (en) | 1992-09-29 | 1994-04-14 | Toray Industries, Inc. | Indole derivative, process for producing the same, and medicinal use thereof |
KR950700065A (ko) * | 1992-12-22 | 1995-01-16 | 마에다 카쭈노수케 | 진해제(Antitussive) |
US5464841A (en) * | 1993-11-08 | 1995-11-07 | Univ Minnesota | Use of delta opioid receptor antagonists to treat immunoregulatory disorders |
SE9304236D0 (sv) * | 1993-12-22 | 1993-12-22 | Astra Ab | New use |
SE9401727D0 (sv) * | 1994-05-18 | 1994-05-18 | Astra Ab | New compounds I |
SE9401728D0 (sv) * | 1994-05-18 | 1994-05-18 | Astra Ab | New compounds II |
US5578725A (en) * | 1995-01-30 | 1996-11-26 | Regents Of The University Of Minnesota | Delta opioid receptor antagonists |
US5994327A (en) * | 1995-11-17 | 1999-11-30 | Astra Ab | Process for the preparation of morphinans |
CA2242609A1 (en) | 1996-01-10 | 1997-07-17 | Smithkline Beecham S.P.A. | Heterocycle-condensed morphinoid derivatives (ii) |
WO1998031684A1 (fr) * | 1997-01-16 | 1998-07-23 | Toray Industries, Inc. | Derives d'indolomorphinane et medicaments/remedes preventifs contre les troubles cerebraux |
US6172078B1 (en) | 1997-03-31 | 2001-01-09 | Toray Industries, Inc. | Quinolinomorphinane derivatives and medicinal use thereof |
US6359111B1 (en) | 1998-05-28 | 2002-03-19 | Neorx Corporation | Opioid receptor targeting |
US7232829B2 (en) | 2001-04-06 | 2007-06-19 | Regents Of The University Of Minnesota | Therapeutic compounds and methods |
US6809104B2 (en) | 2001-05-04 | 2004-10-26 | Tularik Inc. | Fused heterocyclic compounds |
US6858619B2 (en) | 2001-05-04 | 2005-02-22 | Amgen Inc. | Fused heterocyclic compounds |
JP2005530685A (ja) * | 2002-01-25 | 2005-10-13 | リージェンツ オブ ザ ユニバーシティ オブ ミネソタ | 選択的鎮痛剤 |
CN1288158C (zh) * | 2002-07-11 | 2006-12-06 | 东丽株式会社 | 用于预防恶心和呕吐的治疗剂或预防剂 |
BR0316070A (pt) | 2002-11-06 | 2005-09-27 | Tularik Inc | Composto, composição farmacêutica, uso de um composto e, método para modular mchr |
US20080045610A1 (en) * | 2004-09-23 | 2008-02-21 | Alexander Michalow | Methods for regulating neurotransmitter systems by inducing counteradaptations |
EP1809104A4 (en) * | 2004-09-23 | 2009-04-29 | Alexander Michalow | METHODS FOR REGULATING NEUROTRANSMITTER SYSTEMS BY INDUCING COUNTER-ADAPTATIONS |
CN1298718C (zh) * | 2005-03-18 | 2007-02-07 | 中国科学院上海有机化学研究所 | C环连接有吡嗪环的青藤碱衍生物、合成方法及其用途 |
US20070185145A1 (en) * | 2006-02-03 | 2007-08-09 | Royds Robert B | Pharmaceutical composition containing a central opioid agonist, a central opioid antagonist, and a peripheral opioid antagonist, and method for making the same |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4443605A (en) * | 1982-07-30 | 1984-04-17 | Miles Laboratories, Inc. | 7β-Arylalkyl-6α, 7 α-oxymethylene-3-methoxy or 3-hydroxy-4, 5α-epoxy-17 methyl or 17-cycloalkyl-methyl morphinans |
HU196376B (en) * | 1985-05-23 | 1988-11-28 | Sandoz Ag | Process for preparing morphinane derivatives and pharmaceutical compositions containing such compounds |
US4816586A (en) * | 1987-07-29 | 1989-03-28 | Regents Of The University Of Minnesota | Delta opioid receptor antagonists |
US4857533A (en) * | 1988-12-15 | 1989-08-15 | Baker Cummins Pharmaceuticals, Inc. | Method of treatment for autoimmune diseases |
-
1990
- 1990-11-27 JP JP2327453A patent/JP2906654B2/ja not_active Expired - Lifetime
- 1990-11-28 WO PCT/JP1990/001541 patent/WO1991007966A1/ja active IP Right Grant
- 1990-11-28 ES ES90917694T patent/ES2069100T3/es not_active Expired - Lifetime
- 1990-11-28 EP EP90917694A patent/EP0456833B1/en not_active Expired - Lifetime
- 1990-11-28 AT AT90917694T patent/ATE119039T1/de not_active IP Right Cessation
- 1990-11-28 DE DE69017434T patent/DE69017434T2/de not_active Expired - Fee Related
- 1990-11-28 CA CA002045481A patent/CA2045481C/en not_active Expired - Fee Related
- 1990-11-28 AU AU68768/91A patent/AU639053B2/en not_active Ceased
- 1990-11-28 DK DK90917694.3T patent/DK0456833T3/da active
- 1990-11-28 KR KR1019910700795A patent/KR940008032B1/ko not_active IP Right Cessation
-
1991
- 1991-07-26 FI FI913583A patent/FI913583A0/fi not_active Application Discontinuation
- 1991-07-29 NO NO91912940A patent/NO912940L/no unknown
-
1993
- 1993-03-22 US US08/034,669 patent/US5332818A/en not_active Expired - Fee Related
-
1995
- 1995-03-02 GR GR950400451T patent/GR3015266T3/el unknown
Also Published As
Publication number | Publication date |
---|---|
AU639053B2 (en) | 1993-07-15 |
ATE119039T1 (de) | 1995-03-15 |
FI913583A0 (fi) | 1991-07-26 |
EP0456833B1 (en) | 1995-03-01 |
CA2045481A1 (en) | 1991-05-29 |
JP2906654B2 (ja) | 1999-06-21 |
AU6876891A (en) | 1991-06-26 |
NO912940D0 (no) | 1991-07-29 |
EP0456833A4 (en) | 1992-03-18 |
KR940008032B1 (ko) | 1994-09-01 |
NO912940L (no) | 1991-07-29 |
DE69017434D1 (de) | 1995-04-06 |
DK0456833T3 (da) | 1995-05-01 |
CA2045481C (en) | 1995-11-14 |
EP0456833A1 (en) | 1991-11-21 |
GR3015266T3 (en) | 1995-06-30 |
US5332818A (en) | 1994-07-26 |
JPH03223288A (ja) | 1991-10-02 |
DE69017434T2 (de) | 1995-06-29 |
WO1991007966A1 (fr) | 1991-06-13 |
ES2069100T3 (es) | 1995-05-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR920700643A (ko) | 면역억제제 및 그 제조방법 | |
KR920702360A (ko) | 인돌 유도체 | |
KR890006615A (ko) | 헤테로시클릭 치환 아졸 및 아진, 그들의 제조 방법 및 제초제로서의 용도 | |
DE69331843T2 (de) | Xanthine-Derivate als Antidepressiva | |
KR920014816A (ko) | 6환 화합물 | |
ES2156588T3 (es) | Derivados de piperazina como antagonistas de taquiquinina. | |
KR940703841A (ko) | 5-o-데소사미닐에리쓰로노라이드 유도체 | |
CY1107830T1 (el) | Αντικαρκινικα αναλογα | |
KR950702833A (ko) | 진해제(Antitussive) | |
HUP0000343A2 (hu) | 1,3-Propándiol-származékok alkalmazása szervátültetés után fellépő kilökődés megakadályozására | |
KR950000693A (ko) | 프로펜산 유도체 | |
KR970704444A (ko) | 트리아진 유도체 및 의약(triazine derivative and medicine) | |
KR890000421A (ko) | 치환된 인돌리논 유도체를 제조하는 향상된 방법 | |
KR950703503A (ko) | 4-알콕시-2,6-디-t-부틸페놀 유도체(4-ALKOXY-2,6-DI-t-BUTYLPHENOL DERIVATVE) | |
KR910009670A (ko) | 이미다졸 살균제 | |
KR960702463A (ko) | Dc-89 유도체[dc-89 derivative] | |
KR930005999A (ko) | 티오우레아 유도체 및 이를 함유하는 항균제 및 항궤양제 | |
KR920702685A (ko) | 4,6-o- 히드록시포스포릴글루코사민 유도체 | |
KR930023031A (ko) | 아졸 유도체를 함유하는 항아로마타제제 | |
EP0401929A3 (en) | Method of preparing N-oxotetrahydro- -carbolines | |
AR008616A1 (es) | Uso de derivados de fluo-antraciclinona y fluo-antraciclina. | |
KR960703595A (ko) | 항우울제(antidepressant) | |
KR970006283A (ko) | 신규 아민고리 화합물 | |
KR930000499A (ko) | 티옥산테논 항종양제 | |
KR910002853A (ko) | 도파민 효능제 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A201 | Request for examination | ||
E902 | Notification of reason for refusal | ||
AMND | Amendment | ||
E601 | Decision to refuse application | ||
J2X1 | Appeal (before the patent court) |
Free format text: APPEAL AGAINST DECISION TO DECLINE REFUSAL |
|
G160 | Decision to publish patent application | ||
B701 | Decision to grant | ||
GRNT | Written decision to grant | ||
FPAY | Annual fee payment |
Payment date: 19970821 Year of fee payment: 4 |
|
LAPS | Lapse due to unpaid annual fee |